Abstract Details

Title Delayed-release Dimethyl Fumarate Demonstrated No Difference in Clinical Outcomes Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Real-World EFFECT Study

Topic Multiple Sclerosis

Presentation(s) P1 - (-)

Poster/Presentation
Number 362

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
PRESENTER	No disclosure on file
J. Theodore Phillips, MD, PhD, FAAN	No disclosure on file
Jonathan C. Calkwood, MD (Minnesota Center for MS)	No disclosure on file
Anneke Van Der Walt, MD (Alfred Health)	Dr. Van Der Walt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Van Der Walt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Van Der Walt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Van Der Walt has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Van Der Walt has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Van Der Walt has received research support from NHMRC Australia. The institution of Dr. Van Der Walt has received research support from MSRA. The institution of Dr. Van Der Walt has received research support from Roche.
Jinny Min	No disclosure on file
Fan Wu, PhD	No disclosure on file
Catherine Miller	Catherine Miller has received personal compensation for serving as an employee of Biogen. Catherine Miller has received stock or an ownership interest from Biogen.